Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-08-22 | Eric Lev was appointed to the Board effective July 15, 2019. Mr. Lev is currently the Series A Director. Eric Lev has more than 17 years of experience in life science investing. Mr. Lev is a limited partner of the general partner of Ampersand 2018 Limited Partnership. Mr. Lev disclaims beneficial ownership of the shares held by Ampersand, except to the extent of his pecuniary interest therein. |
| 2019-11-14 | Eric Lev Currently serves as a member of the Board. |
| 2020-06-10 | Eric Lev was initially designated as director effective July 15, 2019 by Ampersand as holder of Series A Preferred Stock, and thereby appointed and elected to the Board and was re-designated as director by Ampersand as holder of Series B Preferred Stock, and thereby re-appointed and re-elected to the Board effective January 15, 2020. On January 22, 2020, the Company named Mr. Lev to the Nominating Committee and as Chair to the Regulatory Compliance Committee. Mr. Lev has more than 17 years of experience in life science investing. |
| 2021-09-27 | Eric Lev was initially designated as director effective July 15, 2019 by Ampersand as holder of Series A Preferred Stock, and thereby appointed and elected to the Board and was re-designated as director by Ampersand as a holder of Series B Preferred Stock, and thereby re-appointed and re-elected to the Board effective January 15, 2020. On January 22, 2020, the Company named Mr. Lev to the Nominating Committee and as Chair to the Regulatory Compliance Committee. Messrs. Chan and Lev both voluntarily agreed to waive all non-employee director compensation in 2020. |
Data sourced from SEC filings. Last updated: 2026-03-05